Home › NCT07316166

Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine

Comparison of Suprainguinal Fascia Iliac Block With and Without Dexmedetomidine as an Adjunct to Ropivacaine for Postoperative Analgesia Following Hip Surgery: a Randomized, Double-blinded Study.

Who can join

Ages 18 to 80 · All sexes

Inclusion Criteria:

* Patients undergoing elective total hip arthroplasty
* 18-80 years old
* ASA 1-3 classifications

Exclusion Criteria:

* ASA classification of 4 or greater
* Infection at the site of nerve blockade
* Coagulopathy
* Known allergy to study medications
* Chronic opioid consumption (\>3 months)
* Currently using lidocaine patches
* Pre-existing neuropathy
* A history of CVA
* High grade atrioventricular block (cardiac conduction system impairment)
* Organ dysfunction (cardiac failure, respiratory failure, end stage renal disease, hepatic dysfunction, hypoalbuminemia)
* Morbid obesity (≥40 kg/m2)
* Prior surgery in supra and/or infrainguinal region
* Non-English-speaking participants

About the study

The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.

What is being tested

• Dexmedetomidine (drug)
• Ropivacaine (drug)

Sponsor: Rhode Island Hospital · Participants: 120 · Started: Jan 20, 2026

Contact the study team

• Vendhan Ramanujam, M.D. · Phone: 401-444-5172

Official record on ClinicalTrials.gov — NCT07316166

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.